The FDA approval was based on data from the OPTiM trial (stage IIIB–IVM1c melanoma), which showed that T‐VEC significantly improved the DRR versus subcutaneous GM‐CSF (16.3% vs 2.1%; p < 0.001).27 This evidence concerns the gene CSF2 and melanoma.